Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinvest Headlands LLC

Neither a doctor nor a teaching hospital

Research payments

$5,580,649

519 payments

Through program year 2025, Clinvest Headlands LLC is reported as receiving $5,580,649 in research payments, across 519 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $3,066,060 371
2024 Research $1,629,039 111
2023 Research $885,550 37

Breakdown

Who paid Research payments · program years 2023–2025
  1. Eli Lilly and Company $3,451,136 58 payments
  2. Moderna TX, Inc. $982,374 92 payments
  3. AbbVie, Inc. $540,216 123 payments
  4. Regeneron Pharmaceuticals, Inc. $268,549 98 payments
  5. Pfizer Inc. $140,675 75 payments
  6. Janssen Research & Development, LLC $63,190 23 payments
  7. AstraZeneca Pharmaceuticals LP $39,199 1 payment
  8. Lexicon Pharmaceuticals, Inc. $36,698 15 payments
  9. Sun Pharmaceutical Industries Inc. $36,065 12 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $22,547 22 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $538,623 38 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $508,076 2 payments
  3. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $494,963 3 payments
  4. A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $436,950 2 payments
  5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $435,951 52 payments
  6. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $268,549 98 payments
  7. A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With Ly3549492 Once Daily Compared With Placebo in Adult Participants With Obesity Or Overweight $260,307 4 payments
  8. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized Double-Blind Placebo-Controlled Trial (Triumph-1) $251,320 1 payment
  9. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $250,626 8 payments
  10. A Study of Retatrutide (Ly3437943) Once Weekly in Participants Who Have Obesity Or Overweight and Osteoarthritis of the Knee (Triumph-4) $221,078 3 payments
What the money was spent on Research payments · program years 2023–2025
  1. Patient care $16,127 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record